AVEO Pharmaceuticals, Inc. (AVEO)
(Delayed Data from NSDQ)
$0.94 USD
+0.04 (4.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.94 USD
+0.04 (4.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
New Strong Sell Stocks for July 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
FDA Okays AVEO's NDA Filing for Treating Renal Cell Carcinoma
by Zacks Equity Research
AVEO's new drug application submission for tivozanib as a treatment of relapsed or refractory renal cell carcinoma gets acceptance from the FDA. A decision is expected on Mar 31, 2021.
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
Why Is AVEO (AVEO) Up 24.8% Since Last Earnings Report?
by Zacks Equity Research
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why You Shouldn't Bet Against AVEO Pharmaceuticals (AVEO) Stock
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of -4.00% and -65.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AVEO (AVEO) Up 39.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVEO Stops AML Study on Ficlatuzumab Amid Coronavirus Pandemic
by Zacks Equity Research
AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.
AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat & Sales Miss
by Zacks Equity Research
Even though AVEO Pharmaceuticals (AVEO) reports narrower-than-estimated loss in the fourth quarter, its revenues miss the mark.
AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of 51.72% and -63.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
AVEO Pharmaceuticals (AVEO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CannTrust (CTST) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During CannTrust's (CTST) fourth-quarter earnings call, investor focus will be on the updates pertaining to the company's default status reports and completion of its remediation activities.
What's in Store for Axsome (AXSM) This Earnings Season?
by Zacks Equity Research
On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
What Lies Ahead for Cassava Sciences (SAVA) in Q4 Earnings?
by Zacks Equity Research
During the Q4 investors' call, Cassava Sciences (SAVA) is likely to provide an update on its lead candidate PT-125, which is being developed for the treatment of Alzheimer's disease.
Onconova (ONTX) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Onconova (ONTX) will focus on the updates on lead candidate, Rigosertib, when it reports fourth-quarter 2019 results.
Oncolytics (ONCY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.
What Makes AVEO (AVEO) a New Buy Stock
by Zacks Equity Research
AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
by Zacks Equity Research
AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
Why Is AVEO (AVEO) Down 0.1% Since Last Earnings Report?
by Zacks Equity Research
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal
by Zacks Equity Research
Sarepta (SRPT) expands its footing in the gene therapy field and signs a deal with StrideBio to develop up to eight new treatments.
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) rides high on both earnings and revenue beat in the third quarter. Shares rise.
Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis
by Zacks Equity Research
Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.
Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus
by Zacks Equity Research
Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.
Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales
by Zacks Equity Research
Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.